Literature DB >> 29997149

Importance of Considering Competing Risks in Time-to-Event Analyses: Application to Stroke Risk in a Retrospective Cohort Study of Elderly Patients With Atrial Fibrillation.

Husam Abdel-Qadir1,2,3,4, Jiming Fang3, Douglas S Lee2,3,4, Jack V Tu3,4,5, Eitan Amir3,4,6, Peter C Austin3,4, Geoffrey M Anderson3,4.   

Abstract

BACKGROUND: Ignoring competing risks in time-to-event analyses can lead to biased risk estimates, particularly for elderly patients with multimorbidity. We aimed to demonstrate the impact of considering competing risks when estimating the cumulative incidence and risk of stroke among elderly atrial fibrillation patients. METHODS AND
RESULTS: Using linked administrative databases, we identified patients with atrial fibrillation aged ≥66 years discharged from hospital in ON, Canada between January 1, 2007, and March 31, 2011. We estimated the cumulative incidence of stroke hospitalization using the complement of the Kaplan-Meier function and the cumulative incidence function. This was repeated after stratifying the cohort by presence of prespecified comorbidities: chronic kidney disease, chronic obstructive pulmonary disease, cancer, or dementia. The full cohort was used to regress components of the CHA2DS2VASc (congestive heart failure, hypertension, age, diabetes mellitus, stroke, vascular disease, sex) score on the hazard of stroke hospitalization using the Fine-Gray and Cox methods. These models were subsequently used to predict the 5-year risk of stroke hospitalization. Among 136 156 patients, the median CHA2DS2VASc score was 4 and 84 728 patients (62.2%) had ≥1 prespecified comorbidity. The 5-year cumulative incidence of stroke was 5.4% (95% confidence interval, 5.3%-5.5%), whereas that of death without stroke was 48.8% (95% confidence interval, 48.5%-49.1%). The incidence of both events was overestimated by the Kaplan-Meier method; stroke incidence was overestimated by a relative factor of 39%. The degree of overestimation was larger among patients with non-CHA2DS2VASc comorbidity because of higher incidence of death without stroke. The Fine-Gray model demonstrated better calibration than the Cox model, which consistently overpredicted stroke incidence.
CONCLUSIONS: The incidence of death without stroke was 9-fold higher than that of stroke, leading to biased estimates of stroke risk with traditional time-to-event methods. Statistical methods that appropriately account for competing risks should be used to mitigate this bias.
© 2018 The Authors.

Entities:  

Keywords:  atrial fibrillation; incidence; proportional hazards models; stroke; survival analysis

Mesh:

Year:  2018        PMID: 29997149     DOI: 10.1161/CIRCOUTCOMES.118.004580

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  24 in total

Review 1.  Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice.

Authors:  Rashmi K Murthy; Juhee Song; Akshara S Raghavendra; Yisheng Li; Limin Hsu; Kenneth R Hess; Carlos H Barcenas; Vicente Valero; Robert W Carlson; Debu Tripathy; Gabriel N Hortobagyi
Journal:  NPJ Breast Cancer       Date:  2020-03-25

2.  Prediction of Mortality Incidence in Patients with Chronic Kidney Disease Based on Influential Prognostic Factors with Competing Risks Approach.

Authors:  Anahita Saeedi; Ahmadreza Baghestani; Seyed-Saeed Hashemi-Nazari; Farzanehsadat Minoo; Navid Mohseni; Zahra Esfahani
Journal:  Galen Med J       Date:  2020-12-18

3.  Clinical Characteristics, Outcomes, and Risk Factors for Adverse Events in Elderly and Non-Elderly Japanese Patients With Non-Valvular Atrial Fibrillation - Competing Risk Analysis From the Hokuriku-Plus AF Registry.

Authors:  Toyonobu Tsuda; Kenshi Hayashi; Takeshi Kato; Keisuke Usuda; Takashi Kusayama; Akihiro Nomura; Hayato Tada; Soichiro Usui; Kenji Sakata; Masa-Aki Kawashiri; Noboru Fujino; Masakazu Yamagishi; Masayuki Takamura
Journal:  Circ Rep       Date:  2022-06-15

4.  An empirical comparison of time-to-event models to analyse a composite outcome in the presence of death as a competing risk.

Authors:  Ndamonaonghenda Haushona; Tonya M Esterhuizen; Lehana Thabane; Rhoderick Machekano
Journal:  Contemp Clin Trials Commun       Date:  2020-08-14

5.  Race- and Sex-Specific Population Attributable Fractions of Incident Heart Failure: A Population-Based Cohort Study From the Lifetime Risk Pooling Project.

Authors:  Arjun Sinha; Hongyan Ning; Mercedes R Carnethon; Norrina B Allen; John T Wilkins; Donald M Lloyd-Jones; Sadiya S Khan
Journal:  Circ Heart Fail       Date:  2021-03-25       Impact factor: 8.790

6.  Progression of Mitral Regurgitation in Rheumatic Valve Disease: Role of Left Atrial Remodeling.

Authors:  Nayana F A Gomes; Vicente Rezende Silva; Robert A Levine; William A M Esteves; Marildes Luiza de Castro; Livia S A Passos; Jacob P Dal-Bianco; Alexandre Negrão Pantaleão; Jose Luiz Padilha da Silva; Timothy C Tan; Walderez O Dutra; Elena Aikawa; Judy Hung; Maria Carmo P Nunes
Journal:  Front Cardiovasc Med       Date:  2022-03-11

7.  Cardiorespiratory Fitness and the Risk of First Acute Myocardial Infarction: The HUNT Study.

Authors:  Rajesh Shigdel; Håvard Dalen; Xuemei Sui; Carl J Lavie; Ulrik Wisløff; Linda Ernstsen
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

8.  Association of Early-Stage Breast Cancer and Subsequent Chemotherapy With Risk of Atrial Fibrillation.

Authors:  Husam Abdel-Qadir; Paaladinesh Thavendiranathan; Kinwah Fung; Eitan Amir; Peter C Austin; Geoffrey S Anderson; Douglas S Lee
Journal:  JAMA Netw Open       Date:  2019-09-04

9.  The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study.

Authors:  Husam Abdel-Qadir; Paaladinesh Thavendiranathan; Peter C Austin; Douglas S Lee; Eitan Amir; Jack V Tu; Kinwah Fung; Geoffrey M Anderson
Journal:  J Natl Cancer Inst       Date:  2019-08-01       Impact factor: 13.506

10.  Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy.

Authors:  Thure Filskov Overvad; Anne Gulbech Ording; Peter Brønnum Nielsen; Flemming Skjøth; Ida Ehlers Albertsen; Simon Noble; Anders Krog Vistisen; Inger Lise Gade; Marianne Tang Severinsen; Gregory Piazza; Torben Bjerregaard Larsen
Journal:  Blood Adv       Date:  2022-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.